Gland Pharma Past Earnings Performance

Past criteria checks 1/6

Gland Pharma's earnings have been declining at an average annual rate of -6.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 11.6% per year. Gland Pharma's return on equity is 8.3%, and it has net margins of 12.3%.

Key information

-6.9%

Earnings growth rate

-8.3%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.6%
Return on equity8.3%
Net Margin12.3%
Next Earnings Update04 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Gland Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:543245 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2458,5777,22113,5740
31 Mar 2456,6477,72512,8820
31 Dec 2349,1236,58710,1170
30 Sep 2343,0546,9887,6750
30 Jun 2339,7647,4605,6030
31 Mar 2336,2467,8104,0690
31 Dec 2239,4269,8833,9610
30 Sep 2240,67610,2933,7640
30 Jun 2241,03710,9023,5600
31 Mar 2244,00712,1173,4000
31 Dec 2141,85411,8623,2370
30 Sep 2139,81511,1723,2450
30 Jun 2137,32610,3403,1960
31 Mar 2134,6299,9703,1250
31 Dec 2032,1049,3133,0260
30 Jun 2028,4309,0272,8380
31 Mar 2026,3327,7292,8000
31 Mar 1920,4424,5192,3320
31 Mar 1816,1993,2111,8270
31 Mar 1714,7924,1371,6080

Quality Earnings: 543245 has high quality earnings.

Growing Profit Margin: 543245's current net profit margins (12.3%) are lower than last year (18.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 543245's earnings have declined by 6.9% per year over the past 5 years.

Accelerating Growth: 543245's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 543245 had negative earnings growth (-3.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).


Return on Equity

High ROE: 543245's Return on Equity (8.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies